Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Anesthetic Effect - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2017, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape. Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System) List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Anesthetic Effect (Central Nervous System) pipeline guide List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes, List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Anesthetic Effect - Overview Anesthetic Effect - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Anesthetic Effect - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Anesthetic Effect - Companies Involved in Therapeutics Development 4P Therapeutics LLC Biolab Farmaceutica Ltda Crescita Therapeutics Inc Drawbridge Pharmaceuticals Pty Ltd Expanesthetics Inc Jiangsu Hengrui Medicine Co Ltd Lee's Pharmaceutical Holdings Ltd Lipicard Technologies Ltd Paion AG Phosphagenics Ltd Physica Pharma Primex Pharmaceuticals Oy Proteus SA Recro Pharma Inc Taiwan Liposome Company Ltd The Medicines Company Anesthetic Effect - Drug Profiles alphaxalone - Drug Profile Product Description Mechanism Of Action R&D Progress Aom-0765 - Drug Profile Product Description Mechanism Of Action R&D Progress bupivacaine hydrochloride SR - Drug Profile Product Description Mechanism Of Action R&D Progress Carboetomidate - Drug Profile Product Description Mechanism Of Action R&D Progress cysteine - Drug Profile Product Description Mechanism Of Action R&D Progress EXPS-01 - Drug Profile Product Description Mechanism Of Action R&D Progress EXPS-05 - Drug Profile Product Description Mechanism Of Action R&D Progress EXPS-09 - Drug Profile Product Description Mechanism Of Action R&D Progress Flexicaine - Drug Profile Product Description Mechanism Of Action R&D Progress gabafol - Drug Profile Product Description Mechanism Of Action R&D Progress HSK-3486 - Drug Profile Product Description Mechanism Of Action R&D Progress lidocaine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress lidocaine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress LT-1121 - Drug Profile Product Description Mechanism Of Action R&D Progress LT-1123 - Drug Profile Product Description Mechanism Of Action R&D Progress Methoxycarbonyl Carboetomidate - Drug Profile Product Description Mechanism Of Action R&D Progress Methoxycarbonyl Etomidate - Drug Profile Product Description Mechanism Of Action R&D Progress midazolam hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress neosaxitoxin - Drug Profile Product Description Mechanism Of Action R&D Progress PB-5109 - Drug Profile Product Description Mechanism Of Action R&D Progress PHY-301 - Drug Profile Product Description Mechanism Of Action R&D Progress propofol - Drug Profile Product Description Mechanism Of Action R&D Progress propofol - Drug Profile Product Description Mechanism Of Action R&D Progress propofol - Drug Profile Product Description Mechanism Of Action R&D Progress propofol - Drug Profile Product Description Mechanism Of Action R&D Progress remimazolam - Drug Profile Product Description Mechanism Of Action R&D Progress remimazolam - Drug Profile Product Description Mechanism Of Action R&D Progress RP-1000 - Drug Profile Product Description Mechanism Of Action R&D Progress RP-2000 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Anesthetic Effect - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile Product Description Mechanism Of Action R&D Progress SPR-819 - Drug Profile Product Description Mechanism Of Action R&D Progress Anesthetic Effect - Dormant Projects Anesthetic Effect - Discontinued Products Anesthetic Effect - Product Development Milestones Featured News & Press Releases Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 Sep 01, 2015: Recently Published Study Shows Positive Results for ZiNGO in Pediatric Patients Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Anesthetic Effect, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Anesthetic Effect - Pipeline by 4P Therapeutics LLC, H2 2017 Anesthetic Effect - Pipeline by Biolab Farmaceutica Ltda, H2 2017 Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H2 2017 Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2017 Anesthetic Effect - Pipeline by Expanesthetics Inc, H2 2017 Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017 Anesthetic Effect - Pipeline by Lipicard Technologies Ltd, H2 2017 Anesthetic Effect - Pipeline by Paion AG, H2 2017 Anesthetic Effect - Pipeline by Phosphagenics Ltd, H2 2017 Anesthetic Effect - Pipeline by Physica Pharma, H2 2017 Anesthetic Effect - Pipeline by Primex Pharmaceuticals Oy, H2 2017 Anesthetic Effect - Pipeline by Proteus SA, H2 2017 Anesthetic Effect - Pipeline by Recro Pharma Inc, H2 2017 Anesthetic Effect - Pipeline by Taiwan Liposome Company Ltd, H2 2017 Anesthetic Effect - Pipeline by The Medicines Company, H2 2017 Anesthetic Effect - Dormant Projects, H2 2017 Anesthetic Effect - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
